Jan Mueller-Berghaus

836 total citations
11 papers, 651 citations indexed

About

Jan Mueller-Berghaus is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jan Mueller-Berghaus has authored 11 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Jan Mueller-Berghaus's work include Immunotherapy and Immune Responses (5 papers), CAR-T cell therapy research (4 papers) and T-cell and B-cell Immunology (3 papers). Jan Mueller-Berghaus is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), CAR-T cell therapy research (4 papers) and T-cell and B-cell Immunology (3 papers). Jan Mueller-Berghaus collaborates with scholars based in Germany, Sweden and United States. Jan Mueller-Berghaus's co-authors include Dirk Schadendorf, Walter J. Storkus, Francesco Paolo Schena, Loreto Gesualdo, Ronald M. Bukowski, Tomohide Tatsumi, Lisa Kierstead, James H. Finke, John M. Kirkwood and Elena Ranieri and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and PLoS ONE.

In The Last Decade

Jan Mueller-Berghaus

11 papers receiving 645 citations

Peers

Countries citing papers authored by Jan Mueller-Berghaus

Since Specialization

Citations

This map shows the geographic impact of Jan Mueller-Berghaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Mueller-Berghaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Mueller-Berghaus more than expected).

Fields of papers citing papers by Jan Mueller-Berghaus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Mueller-Berghaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Mueller-Berghaus. The network helps show where Jan Mueller-Berghaus may publish in the future.

Co-authorship network of co-authors of Jan Mueller-Berghaus

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Mueller-Berghaus. A scholar is included among the top collaborators of Jan Mueller-Berghaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Mueller-Berghaus. Jan Mueller-Berghaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer 2021 ·ESMO Open ·(unknown), Julio Delgado, Armando A. Genazzani, Jan Mueller-Berghaus, Cristina Migali, (unknown), Hilke Zander, Harald Enzmann, Francesco Pignatti	29
2	EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma 2020 ·The Oncologist ·(unknown), Jan Mueller-Berghaus, Claire Beuneu, (unknown), Benjamin Hofner, Frank Pétavy, Kyriaki Tzogani, Anne M. Miermont, Koen Norga, Olga Kholmanskikh, (unknown), Martina Schuessler‐Lenz, Tomas Salmonson, Christian Gisselbrecht, (unknown), Francesco Pignatti	47
3	The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use 2015 ·The Oncologist ·Iordanis Gravanis, Kyriaki Tzogani, Paula B. van Hennik, Pieter A. de Graeff, Petra M. Schmitt, Jan Mueller-Berghaus, Tomas Salmonson, Christian Gisselbrecht, Edward Laane, Lothar Bergmann, Francesco Pignatti	24
4	In vitro cytokine release assays for predicting cytokine release syndrome: The current state-of-the-science. Report of a European Medicines Agency Workshop 2010 ·Cytokine ·(unknown), Thomas T. Kawabata, Robin Thorpe, Beatriz Silva Lima, Karin Cederbrant, Stephen Poole, Jan Mueller-Berghaus, Marc Pallardy, (unknown)	28
5	PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells 2010 ·Blood ·Ravikumar Muthuswamy, Jan Mueller-Berghaus, Uwe Haberkorn, Todd A. Reinhart, Dirk Schadendorf, Paweł Kaliński	96
6	B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis 2007 ·PLoS ONE ·Selma Ugurel, Ranjit K. Thirumaran, Sandra Bloethner, Andreas Gast, Antje Sucker, Jan Mueller-Berghaus, Werner Rittgen, Kari Hemminki, Jürgen C. Becker, Rajiv Kumar, Dirk Schadendorf	103
7	Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes 2006 ·Melanoma Research ·Sandra Bloethner, Kari Hemminki, Ranjit K. Thirumaran, Bowang Chen, Jan Mueller-Berghaus, Selma Ugurel, Dirk Schadendorf, Rajiv Kumar	16
8	Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2–Derived Epitope Identified in HLA-DRB10301 Transgenic Mice 2005 ·Clinical Cancer Research* ·Annette Paschen, Mingxia Song, Wolfram Osen, Xuan Duc Nguyen, Jan Mueller-Berghaus, (unknown), Nadine Daniel, Mariel Donzeau, Wolfgang Nagel, Harald Kropshofer, Dirk Schadendorf	15
9	Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma 2002 ·The Journal of Experimental Medicine ·Tomohide Tatsumi, Lisa Kierstead, Elena Ranieri, Loreto Gesualdo, Francesco Paolo Schena, James H. Finke, Ronald M. Bukowski, Jan Mueller-Berghaus, John M. Kirkwood, William W. Kwok, Walter J. Storkus	242
10	In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. 2002 ·PubMed ·(unknown), Walter J. Storkus, Jan Mueller-Berghaus, W Knapp, Albert B. DeLeo, Kazuaki Chikamatsu, Theresa L. Whiteside	18
11	An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich's ataxia) gene. 1998 ·Diabetes ·Michael Ristow, (unknown), (unknown), (unknown), Matthias Vorgerd, Jörg Kotzka, Birgit Knebel, Jan Mueller-Berghaus, C. Epplen, Andreas Pfeiffer, C. Ronald Kahn, Alessandro Doria, Wilhelm Krone, (unknown)	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact